Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. FDA for its Abbreviated New Drug Application for Divalproex Sodium Extended-release (Divalproex ER) Tablets, 250 mg and 500 mg.
The details can be read here.
No comments:
Post a Comment